KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBITDA (2018 - 2025)

Historic EBITDA for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $31.7 million.

  • Aurinia Pharmaceuticals' EBITDA rose 11388.96% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 45231.01%. This contributed to the annual value of $5.8 million for FY2024, which is 10751.07% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its EBITDA stood at $31.7 million for Q3 2025, which was up 11388.96% from $21.4 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year EBITDA high stood at $31.7 million for Q3 2025, and its period low was -$50.4 million during Q1 2021.
  • For the 5-year period, Aurinia Pharmaceuticals' EBITDA averaged around -$15.0 million, with its median value being -$13.4 million (2023).
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' EBITDA crashed by 9425.03% in 2021, and later skyrocketed by 288926.08% in 2025.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' EBITDA stood at -$33.4 million in 2021, then rose by 23.37% to -$25.6 million in 2022, then fell by 4.21% to -$26.7 million in 2023, then skyrocketed by 104.38% to $1.2 million in 2024, then soared by 2616.97% to $31.7 million in 2025.
  • Its EBITDA stands at $31.7 million for Q3 2025, versus $21.4 million for Q2 2025 and $23.2 million for Q1 2025.